Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1801)	2/22/1999 11:02:00 PM
From: Neuroguy	Respond to of 10280

Peter - thanks for the reply I agree that ultimately receptor subtype-specific cocktails will be developed to cater for individuals. Lilly - well, they certainly are well placed to do this. They also have another drug in their pipeline that is equipotent to valium without any obvious side effects (it's an mGluR2 agonist) which should generate great revenues downstream, should they chase after it. Reuptake inhibitors do cause a rise in transmitter levels leading to increased postsynaptic receptor activation, as the first abstract you listed detailed. However, this underlies an acute effect of antidepressants that was long ago ruled out as a therapeutic mode of action. Instead, it appears to be the secondary change in receptor density that takes 3-6 weeks to develop that underlies the therapeutic actions. In the case of sexual dysfunction, there is a population of serotonergic neurons in the brainstem that mediates descending inhibition of the 'sexual reflex' (orgasm). By potentiating the effects of serotonin in this pathway with SSRIs, one necessarily suppresses the sexual reflex. Getting around this problem may require compounds that do not act on the serotonin reuptake carriers in this pathway. That may prove tricky, as they may be the same ones required for the psychotherapeutic effect. Neuroguy